An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Kennedy called for broader availability to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how policymakers view compounded peptide therapies, which have drawn growing interest from users seeking alternatives to conventional drugs. Scientists say peptide treatments could reshape approaches to stubborn infections, though concerns about quality persist. The committee's endorsement of four peptides opens the door for more widespread prescribing, even as critics warn of limited evidence. Sector observers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on particular peptide candidates.